Roche: Genentech buys US biotechnology firm Jecure
(CercleFinance.com) - Roche biotechnology unit Genentech said it had agreed to buy California-based Jecure Therapeutics to gain access to its portfolio of immunomodulatory protein (NLRP3) inhibitors.
Thanks to this acquisition, Genentech will obtain full rights to Jecure's entire pre-clinical portfolio of NLRP3 inhibitors, that may play a role in a number of serious diseases.
Studies have linked NLRP3 inflammasomes to several inflammatory and autoimmune disorders, such as non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD) and cardiovascular diseases.
Jecure began operations in 2015. The company raised 20 million dollars in 2017 to continue to develop its experimental drugs.
The terms of the deal were not disclosed.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Thanks to this acquisition, Genentech will obtain full rights to Jecure's entire pre-clinical portfolio of NLRP3 inhibitors, that may play a role in a number of serious diseases.
Studies have linked NLRP3 inflammasomes to several inflammatory and autoimmune disorders, such as non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD) and cardiovascular diseases.
Jecure began operations in 2015. The company raised 20 million dollars in 2017 to continue to develop its experimental drugs.
The terms of the deal were not disclosed.
Copyright (c) 2018 CercleFinance.com. All rights reserved.